Jun 10, 2020 8:00am EDT Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Feb 11, 2020 8:00am EST Dermata Therapeutics Announces Completion of Enrollment in a Phase 2b Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris
Jul 09, 2019 8:00am EDT Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
Apr 13, 2017 8:00am EDT Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases
Feb 16, 2017 9:00am EST Dermata Therapeutics, LLC Closes a $5 Million Series 1a Financing and Secures a $5 Million Credit Facility with Silicon Valley Bank
Jan 18, 2017 12:00pm EST Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study
Nov 17, 2016 12:00pm EST Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Atopic Dermatitis Study
Sep 28, 2016 8:00am EDT Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients
Sep 20, 2016 8:00am EDT Dermata Therapeutics, LLC Announced the Addition of Wendell Wierenga, Ph.D. to its Board of Directors
May 16, 2016 8:00am EDT Dermata Therapeutics, LLC Announces Initiation of Phase 1 Pharmacokinetic Study
